Effect of vitamin supplementation on serum oxidized low-density lipoprotein levels in male subjects with cardiovascular disease risk factors. by , Akbarzadeh, S et al.
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Introduction 
Epidemiological studies have shown an 
inverse relationship between plasma 
antioxidant vitamins levels (vitamin C and E 
and ß-carotene) and mortality from coronary 
heart disease (1). Many studies have reported 
that the combination of vitamins E and C are 
more potent in preventing atherosclerosis, and 
the beneficial effects of vitamin E could be 
enhanced through the vitamin E regeneration 
by the assist of vitamin C (2). Oxidized low-
density lipoproteins (ox-LDLs) play a 
substantial role in atherogenesis. In fact, 
circulating ox-LDL concentrations have been 
recognized as a risk factor for cardiovascular 
disease (CVD) (3). LDL is an imperative 
target of oxidation, and oxidative 
modification of LDL is a key step in the 
pathogenesis of atherosclerosis. The primary 
interest in ox-LDL was based on two critical 
observations. Firstly, ox-LDL was cytotoxic 
to endothelial and smooth muscle cells (4). 
Secondly, uptake of native LDL by 
macrophages occurred at sufficiently low rate 
to prevent foam cell formation, but uptake of 
ox-LDL was unregulated and led to 
macrophage foam cell formation and 
subsequent atherosclerosis (5). Elevated          
ox-LDL is independently associated with 
increased atherosclerotic burden and 
increased CHD risk (6). It is now clear that 
ox-LDL, with its many oxidatively modified 
lipids and degradation products, contributes to 
the pathophysiology of both the initiation and 
progression of atherosclerosis (7). Ox-LDL 
concentrations are strongly correlated with 
plasma LDL concentrations. The latter is thus 
a key factor in determining absolute plasma 
ox-LDL concentration (8). The importance of 
ox-LDL in atherogenesis has been further 
confirmed by the use of specific antibodies to 
oxidize LDL shown to be local to 
atherosclerotic lesions in the vessel wall (9). 
It is previously established that oxidative 
modifications of LDL may result in lipid-
induced atherogenesis. All major cells of the 
arterial wall exert oxidative modifications on 
LDL particles (10).  LDL, which is the major 
carrier of cholesterol and lipids in the blood 
(11), intrudes into the intima of lesion-prone 
arterial sites, where it is oxidized over time by 
oxidants, generated by local vascular cells              
or enzymes, to a form with atherogenic 
properties. There are indirect evidences            
from “in vivo” oxidation studies that               
have assessed the antioxidant supplementation in 
animals whose outcomes have supported 
significant reductions in lesion formation            
and LDL oxidation through antioxidant 
supplementation (1). Alpha-tocopherol 
supplementation in normal volunteers decreased 
LDL oxidation and its cytotoxic effect on 
endothelial cells (12). The antioxidants ß-
carotene, α-tocopherol, and vitamin C have 
implicated benevolent effects on blocking or 
slowing down the atherosclerotic process 
through the inhibition of LDL oxidation (13).  
 
Materials and Methods 
This study was carried out at the Persian Gulf 
Health Research Centre (PGHRC) of Bushehr 
University of Medical Sciences. Written 
informed consent was obtained from each 
participant prior to the study entry and ethical 
approve was obtained from deputy of research 
of Bushehr University of Medical Sciences, 
Iran. 
The main objectives of this study were to 
assess the effects of antioxidant vitamins on 
biomarkers of CVD in male subjects with CVD 
risk factors, at baseline and after 12 weeks of 
supplementation with vitamin E, C, ß-carotene, 
and the combined supplements. Secondary 
measurements included anthropometry, 
biochemical indices and dietary intake that were 
carried out at baseline and after 12 weeks. 
Subjects were recruited through advertisement 
in local newspapers and announcement via 
radio. Inclusion criteria were age ≥ 40 years, 
intake of vitamin and mineral supplements 
during the past 3 months and elevated risk of 
cardiovascular disease, defined as the presence 
of the following six known disorders: 
hypertension, dyslipidemia, type 2 diabetes, 
obesity, family history of premature CVD, and 
smoking. Participants with any of the following 
conditions were excluded from the study: CVD 
(angina pectoris, myocardial infarction, stroke, 
Saeid Najafpour Boushehri et al 
         Iran J Basic Med Sci, Vol. 15, No. 4, July-Aug 2012  960
peripheral arterial occlusive disease), heart 
failure, cardiac arrhythmia, type I diabetes, 
renal insufficiency, active liver disease or 
cirrhosis and other severe diseases (e.g. cancer, 
gastrointestinal disorders). People who were 
unwilling to fulfill the study medications or 
used out-of-study vitamin supplements were 
excluded as well. Two hundred individuals who 
met the inclusion criteria were recruited into the 
study at baseline and were divided into 5 groups 
of C, E, B, COM and P. Vitamin supplements 
were prescribed daily for all the participants in 
the treatment groups. The group E took vitamin 
E (400 IU), group C took vitamin C (500 mg), 
group B took ß-carotene (15 mg), and COM 
group took vitamin E plus C and ß-carotene by 
oral supplementation for 12 weeks. Subjects in 
the control group were requested not to alter 
their behavior with regards to supplements 
intake. They were advised to continue with their 
usual dietary habits and lifestyle. Blood samples 
were collected after 12 hr of last meal. Fasting 
venous blood samples were taken for 
measurement of plasma concentration of ox-
LDL, and serum concentrations of vitamin E, C, 
ß-carotene, FBS, TG, T-Chol, HDL, and LDL 
cholesterol. Oxidized LDL level was measured 
using a commercially oxidized LDL ELISA kit 
(Mercodia Inc, Sweden). The Statistical 
Package for the Social Sciences (SPSS 
windows version 15) was applied for statistical 
analysis. Normality of distribution was 
evaluated by Kolmogorov-Smirnov test. Since 
the normality of distribution for biomarkers          
for CVD was violated, nonparametric statistics         
like Wilcoxon was employed. For variables  
that met normality of distribution, Analysis of 
variance (ANOVA), Independent t test               
and paired sample t test were utilized to identify 
the mean differences between and within 
groups. Statistical significance has been 
assigned at level of P< 0.05. 
 
Results 
A total of 181 out of 200 men completed the 
study. An overall of 19 people left the study 
due to personal reasons out of which five 
were from group C, three from E, six from B 
and five from P.  The mean intakes for 
calories in the vitamin C, E, beta carotene, 
combined and control groups were 2517±124 
kcal, 2570±209 kcal, 2484 ± 274 kcal, 2506 ± 
212 kcal, and 2573±210 kcal, respectively. 
The major sources of energy were CHO and 
fat. No significant differences were found in 
the mean calorie intake and nutrient content 
of participants’ diet within groups.           
Table 1 shows the baseline anthropometric 
measurements of the participants. The mean 
values of participants’ BMI were 27.86±4.26 
kg/m2, 27.28±4.05 kg/m2, 26.90±4.66 kg/m2, 
26.84±3.71 kg/m2, and 27.06±3.73 kg/m2 in 
the groups C, E, B, COM and P respectively. 
At baseline, there were no significant 
differences (P> 0.05) in the mean values 
anthropometric measurements within the 
supplementation and control groups. 
Table 2 and Table 3 show the mean 
changes in fasting blood sugar and lipid 
profile before and after the intervention 
within groups. In vitamin C group the 
observed mean changes were as it follows: in 
FBS -2.51±2.25 mg/dl, TG 38±17.58 mg/dl, 
TC 6.4±5.31 mg/dl, HDL-C -3.41±1.87 mg/dl 
and LDL-C 4.60±4.89 mg/dl. However, there 
were no significant differences (P> 0.05) in 
the mean values of FBS and lipid profile 
within groups. The mean changes in vitamin 
E group were -7.91±11.51 mg/dl for FBS, 
17.56±14.49 mg/dl for TG, -5.86±3.69 mg/dl 
for TC, -.961±1.00 mg/dl for HDL-C and -
2.06±4.26 mg/dl for LDL-C. The values for 
group B were respectively 3.177±3.61 mg/dl, 
7.91±10.66 mg/dl, -0.02± 3.19 mg/dl, -1.95± 
1.25 mg/dl and 6.35± 3.95 mg/dl. Similarly 
no significant differences were detected in the 
mean values of FBS, lipid profile within 
groups E and B. The mean changes at the 
baseline in the combined (C+E+ ß-carotene) 
group were as follows: FBS (3.27±3.85 
mg/dl), TG (13.35±19.26 mg/dl), TC 
(4.02±4.36 mg/dl), HDL-C (-0.26±1.35 
mg/dl), LDL-C (-2.95±4.35 mg/dl). Placebo 
(P) group showed the following changes: FBS 
(-0.65±1.73 mg/dl), TG (6.60±11.17 mg/dl), 
TC (3.91±2.42 mg/dl), HDL-C (-1.55±1.17 
mg/dl), LDL-C (64.40±40.88 mg/dl). 
Oxidized-Low Density Lipoproteins 
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Table 1. The anthropometric measurements at the baseline and after the intervention (mean± SD) 
 
 C group (n= 37) E group (n= 37) B group (n= 34) COM group (n= 40) P group (n= 34)
Parameters    
 
 
 
 
 
 
 
 
Height (cm) 172.64±5.78 174.45±6.38 176.85±7.9 175.82±8.8 173.90±7.8 
Weight (kg)      
before 83.25±14.69 83.28±14.82 84.19±16.0 83.40±162 82.06±13.5 
after 83.36±14.58 83.63±15.35 84.2±16.16 84.38±192 82.13±13.7 
P value 0.236 0.357 0.540 0.664 0.740 
BMI (kg/m2)      
before 27.86±4.26 27.28±4.05 26.90±4.66 26.84±3.1 27.06±3.73 
after 27.91±4.27 27.39±4.27 26.91±4.68 27.15±4.92 27.08±3.70 
P value 0.138 0.396 0.722 0.691 0.679 
Note: SD, standard deviation; BMI, body mass index. *P< 0.05 
 
 
There were also no significant differences 
in the values of the FBS and lipid profile 
within groups COM and P (P> 0.05). 
The initial mean values of ox-LDL were  
86.93 ± 26.30 U/l in group C, 94.52 ± 38.40 U/l 
in group E, 79.73 ± 2.07 U/l in group B, 85.97 ± 
23.07 U/l in combined group, and 84.90 ± 14.66 
U/l in group P. After 12 weeks of intervention, 
the mean changes in the ox-LDL level were -
15.93± 5.33, -22.56± 5.89, -13.73± 2.9, -16.40± 
3.49 and -1.70± 1.31 respectively within C, E, B, 
COM and P groups. The highest amount of 
changes belonged to the participants in vitamin 
E group (-23.86%). Wilcoxon methods showed 
significant differences in the before and after 
intervention values of oxLDL concentrations in 
groups C, E, B, and COM (P< 005). No 
significant changes were observed in the mean 
values of oxLDL concentrations in the control 
group. 
 
Discussion  
The current study illustrated that vitamin C 
(500 mg), vitamin E (400 IU), ß-carotene       
(15 mg), and the combination of these 
supplements are associated with reduced 
serum oxidized LDL (ox-LDL) levels. In more 
specific, there is a significant difference 
between vitamins C, E, ß-carotene and the 
combined groups before and after 12 weeks 
supplementation. 
Strong relationships between antioxidant 
vitamins (C, E, and ß-carotene) and oxLDL have 
been reported previously in the literatures. 
Though the results of current study demonstrated 
considerable reduction in percentage of the 
changes of ox-LDL in the intervention groups 
(17.31- 23.86). The findings of the current study 
are consistent with those of Reaven et al (14), 
Jialal et al (15), and Hodis et al (16).  
In a study by Hodis et al (16), it was reported 
that α-tocopherol supplementation (400 IU/day) 
significantly raised plasma vitamin E levels        
(P< 0.0001), reduced circulating ox-LDL          
(P= 0.03) and reduced LDL oxidative 
susceptibility (P< 0.01). Supplementation with 
vitamin E (1,600 mg/day) for 3 months has 
shown a decrease in LDL oxidation by 30-40%            
(14). The minimum dose of 400 IU/d of                    
α-tocopherol supplementation is needed to 
significantly reduce the LDL susceptibility to 
oxidation (15).  
Princen et al (17) found that the lag phase 
of LDL oxidation was significantly increased 
by as little as 25 mg/day α-tocopherol 
supplementation. However, it took at             
least 400 mg/day to show significant 
reductions in the rate of oxidation.                  
α-Tocopherol supplementation in normal 
volunteers decreased LDL oxidation and its 
cytotoxic effect on endothelial cells (12). 
Saeid Najafpour Boushehri et al 
         Iran J Basic Med Sci, Vol. 15, No. 4, July-Aug 2012  962
 
 
 
Table 2. Changes for fasting blood sugar and lipid profiles at the baseline and after the intervention in C and E groups (mean± SD and Meand±SEd) 
 
Note: SD = Standard deviation; FBS, fasting blood sugar; TC, total cholesterol; TG, triglycerides; LDL-C, low density lipoprotein cholesterol; HDL-C, high density 
lipoprotein; meand = mean of differences; SEd = standard error of differences 
 
 
 
 
Table 3.  Changes for fasting blood sugar and the lipid profiles at the baseline and after the intervention in ß-carotene and combined groups (mean±SD and mean d ±SE)d 
 
Parameters B group (n=34) COM group (n=40) P group (n=35) 
Before 
Mean±SD 
After 
Mean±SD 
Mean d ±SE d 
(within groups) 
P 
value 
Before 
Mean±SD 
After 
Mean±SD 
Mean d ±SEd 
(within 
groups) 
P 
value 
Before 
Mean±SD 
After 
Mean±SD 
Meand ±SEd 
(within 
groups) 
P 
value 
FBS (mg/dl) 97.02±45.57 91.41±42.08 3.177±3.61 0.386 96.85±37.55 94.72±28.53 3.27±3.85 0.401 83.08±20.543 83.74±21.91 -0.65±1.73 0.708 
TG (mg/dl) 220.67±123.28 212.76±116.38 7.91±10.66 0.463 233.75±161.96 220.40±93.42 13.35±19.26 0.492 176.68±91.26 170.08±80.40 6.60±11.17 0.559 
TC (mg/dl) 196.85±32.59 197.05±34.22 -0.02±3.19 0.949 209.30±31.92 205.27±44 4.02±4.36 0.363 199.11±36.48 190.91±26.62 3.91±2.42 0.115 
HDL-C (mg/dl) 41.32±9.73 43.28±9.68 -1.95±1.25 0.128 42.02±11.78 42.29±10.43 -0.26±1.35 0.847 40.41±8.57 41.96±9.19 -1.55±1.17 0.196 
LDL-C (mg/dl) 110.23±29.05 103.88±34.99 6.35±3.95 0.118 118.50±31.36 121.50±28.95 -2.95±4.35 0.502 160.45±24.60 114.05±23.70 64.40±40.88 0.264 
Note: SD= Standard deviation; FBS, fasting blood sugar; TC, total cholesterol; TG, triglycerides; LDL-C, low density lipoprotein cholesterol; HDL-C, high density 
lipoprotein; meand = mean of differences; SEd = Standard Error of Differences 
 
Parameters 
C group (n=35) E group (n=37)
Before 
Mean±SD 
After 
Mean±SD 
Mean d ±SE d 
(within groups) P value 
Before 
Mean±SD 
After 
Mean±SD 
Mean d ±SE d 
(within groups) P value 
FBS (mg/dl) 86.17±24.62 88.28±27.92 -2.51±2.25 0.261 94.29±39.73 102.21±77.20 -7.91±11.51 0.496 
 TG (mg/dl) 206.65±131.38 168.65±87.16 38±17.58 0.381 241.24±159.66 223.67±129.59 17.56±14.49 0.233 
TC (mg/dl) 218.65±36.31 212.25±41.14 6.4±5.31 0.237 208.75±41.31 214.62±45.49 -5.86±3.69 0.121 
HDL-C (mg/dl) 45.65±7.95 49.07±12.43 -3.41±1.87 .078 40.18±11.39 41.14±10.36 -.961±1.00 0.345 
LDL-C  (mg/dl) 132.05±28.32 127.45±29.88 4.60±4.89 .354 124.08±45.59 126.14±40.92 -2.06±4.26 0.631 
Vitamin C (µmol/l) 35.15±7.57 48.43±9.95 -13.27±1.26 .000* 35.83±11.62 34.57±9.75 1.26±1.30 0.338 
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Table 4. Changes in the oxLDL (U/l) in serum at the baseline and after the intervention (mean±SD and meand±SEd) 
 
oxLDL (U/l) 
 C group E group B group COM group P group 
Before 86.93± 26.30 94.52 ± 38.40 79.73 ±2.07 85.97±23.07 84.90± 14.661 
After  70.99± 16.46 71.95 ± 17.897 65.99±16.72 69.57± 14.99 83.20± 15.68 
Meand ±SEd (within groups) -15.93± 5.33 -22.56± 5.89 -13.73± 2.9 -16.40± 3.49 -1.70± 1.31 
Changing Percent -18.32 -23.86 -17.31 -19.07 -2.0 
P value  0.005* 0.000* 0.000* *0.000 0.213 
* P value <0.05 is significantly different   
Test non-parametric, Wilcoxon, was used to compare pre-post tests 
 
 
In a study by Princen et al (17), authors 
concluded that intake of vitamin E (1,000 
IU/day) for 7 days was sufficient to increase 
plasma alpha-tocopherol and LDL 3.0- and 2.4-
folds respectively. Additionally the oxidation 
resistance of LDL was elevated up to 41%, and 
the rate of oxidation was lowered by -19% 
significantly.  
A short study on vitamin C supplementation 
showed that the exposure of healthy smokers for 
4 weeks with 1000 mg ascorbate per day could 
result in an increase in plasma ascorbate level 
and a significant reduction in LDL oxidative 
susceptibility (18). 
Supplementation with 400 mg/day vitamin         
E in normal volunteers has been also effective         
to lower LDL oxidation resulting in a reduction   
in its cytotoxic effect on endothelial                       
cells correspondingly (12). In 1996, Omenn          
et al (13) demonstrated that antioxidants beta-
carotene, α-tocopherol, and vitamin C are 
involved with prevention or delay in the 
atherosclerotic process by inhibiting LDL 
oxidation. 
 
Conclusion  
The findings of this study demonstrated that 
supplementation of antioxidant vitamins 
decreased harmful biomarkers for cardiovascular 
diseases such as oxLDL. To reduce the risk of 
CVD occurrence, the individuals at risk should 
be encouraged for a daily consumption of 
antioxidant vitamins supplementation. 
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